Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ShigETEC vaccine in Bangladeshi adults and children
NCT05987488Phase 1Completed
- Sponsor
- Eveliqure Biotechnologies
- Start
- Nov 2023
- Primary completion
- Dec 2025
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in shigellosis and Enterotoxigenic Escherichia coli diarrhea comparing ShigETEC Vaccine with Placebo (2 arms). Primary endpoints: Solicited Reactogenicity at 72 hours, Unsolicited Adverse Event at 56 days and 1 more. Started Nov 2023; status: completed.
02
Drugs
ShigETEC
03
Conditions
shigellosisEnterotoxigenic Escherichia coli diarrhea
Beyond the preview
Go deeper on NCT05987488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05987488.